{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+regimen&page=52",
    "query": {
      "intervention": "Control regimen",
      "page": 52
    },
    "page_size": 10
  },
  "pagination": {
    "page": 52,
    "page_size": 10,
    "total_count": 1569,
    "total_pages": 157,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+regimen&page=53&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+regimen&page=51&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T03:43:48.681Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03926624",
      "title": "Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "DFP-10917",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Cladribine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Delta-Fly Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 167,
      "start_date": "2019-11-22",
      "completion_date": "2026-01-07",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-11-07T03:43:48.681Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03926624"
    },
    {
      "nct_id": "NCT07661459",
      "title": "Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Asprin",
          "type": "DRUG"
        },
        {
          "name": "Loratadine",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen Avoidance",
          "type": "BEHAVIORAL"
        },
        {
          "name": "THC Avoidance",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Val Adams",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 98,
      "start_date": "2026-06-26",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-11-07T03:43:48.681Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07661459"
    },
    {
      "nct_id": "NCT01983241",
      "title": "Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Emphysema in Alpha-1 PI Deficiency"
      ],
      "interventions": [
        {
          "name": "Alpha-1 MP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.9% Sodium Chloride for Injection, USP",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 345,
      "start_date": "2014-04-01",
      "completion_date": "2026-08-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-11-07T03:43:48.681Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Leesburg",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01983241"
    },
    {
      "nct_id": "NCT01380106",
      "title": "Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Lenalidomide 15mg",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide 25mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston VA Research Institute, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2010-08",
      "completion_date": "2017-09-11",
      "has_results": true,
      "last_update_posted_date": "2021-01-25",
      "last_synced_at": "2026-11-07T03:43:48.681Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Hines, Illinois + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hines",
          "state": "Illinois"
        },
        {
          "city": "Jamaica Plain",
          "state": "Massachusetts"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01380106"
    },
    {
      "nct_id": "NCT01197521",
      "title": "Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "fostamatinib",
          "type": "DRUG"
        },
        {
          "name": "placebo, fostamatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 923,
      "start_date": "2010-09",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-04-07",
      "last_synced_at": "2026-11-07T03:43:48.681Z",
      "location_count": 41,
      "location_summary": "Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01197521"
    },
    {
      "nct_id": "NCT03412747",
      "title": "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Plaque Psoriasis",
        "Moderate to Severe Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Bimekizumab",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 478,
      "start_date": "2018-01-26",
      "completion_date": "2020-02-26",
      "has_results": true,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-11-07T03:43:48.681Z",
      "location_count": 23,
      "location_summary": "Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Luis Obispo",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03412747"
    },
    {
      "nct_id": "NCT06544733",
      "title": "Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-Infection"
      ],
      "interventions": [
        {
          "name": "Lepetegravir",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir pacfosacil",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Match BVY",
          "type": "DRUG"
        },
        {
          "name": "Bictegravir/emtricitabine/tenofovir alafenamide",
          "type": "DRUG"
        },
        {
          "name": "Lepetegravir/Lenacapavir pacfosacil FDC",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Match GS1720/GS-4182 FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 675,
      "start_date": "2024-08-20",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-11-07T03:43:48.681Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06544733"
    },
    {
      "nct_id": "NCT00366938",
      "title": "Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Lumiracoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1464,
      "start_date": "2003-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-05-21",
      "last_synced_at": "2026-11-07T03:43:48.681Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00366938"
    },
    {
      "nct_id": "NCT04070326",
      "title": "A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "Lanadelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 21,
      "start_date": "2019-08-19",
      "completion_date": "2021-10-30",
      "has_results": true,
      "last_update_posted_date": "2022-05-26",
      "last_synced_at": "2026-11-07T03:43:48.681Z",
      "location_count": 11,
      "location_summary": "Santa Monica, California • Walnut Creek, California • Centennial, Colorado + 8 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04070326"
    },
    {
      "nct_id": "NCT03670953",
      "title": "A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease (Disorder)"
      ],
      "interventions": [
        {
          "name": "IR CD-LD",
          "type": "DRUG"
        },
        {
          "name": "IPX203 ER CD-LD",
          "type": "DRUG"
        },
        {
          "name": "Placebo Matching IPX203",
          "type": "OTHER"
        },
        {
          "name": "Placebo Matching IR CD-LD",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Impax Laboratories, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 630,
      "start_date": "2018-11-06",
      "completion_date": "2021-06-15",
      "has_results": true,
      "last_update_posted_date": "2023-02-09",
      "last_synced_at": "2026-11-07T03:43:48.681Z",
      "location_count": 56,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03670953"
    }
  ]
}